KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Intangibles: 2011-2024

Historic Change in Intangibles for Biomarin Pharmaceutical (BMRN) over the last 10 years, with Dec 2024 value amounting to $12.0 million.

  • Biomarin Pharmaceutical's Change in Intangibles rose 95.47% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year decrease of 52.37%. This contributed to the annual value of $12.0 million for FY2024, which is 9.84% up from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Change in Intangibles is $12.0 million, which was up 9.84% from $10.9 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Change in Intangibles registered a high of $23.6 million during FY2021, and its lowest value of $10.6 million during FY2022.
  • In the last 3 years, Biomarin Pharmaceutical's Change in Intangibles had a median value of $10.9 million in 2023 and averaged $11.2 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Change in Intangibles increased by 26.26% in 2020, and later tumbled by 55.25% in 2022.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Change in Intangibles stood at $23.2 million in 2020, then climbed by 1.90% to $23.6 million in 2021, then slumped by 55.25% to $10.6 million in 2022, then rose by 3.20% to $10.9 million in 2023, then grew by 9.84% to $12.0 million in 2024.